Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Simcere Files to Test Innovative Cancer Drug from US Biopharma

publication date: Mar 11, 2011
View a Printer Friendly version of this page, allowing you to print the page.
Simcere Pharma has filed an Investigational New Drug (IND) application with the SFDA to start a Phase I trial of a novel monoclonal antibody intended to treat various forms of solid-tumor cancer. The mAb, known as APX003, was discovered by Apexigen of California. Simcere collaborated with Apexigen on the IND-enabling studies and owns China rights to the molecule. To advance its own development program, Apexigen has licensed China rights for three of its molecules to three China companies and collaborated with them on pre-clinical development. More details....

Stock Symbol: (NYSE: SCR)     Share this with colleagues:  


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China